Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Vascular disorders – page 53

  • 846 clinical trials
  • 351 recruiting
  • 382 conditions
  • 28 countries

Conditions in this area

382 conditions with trials, the busiest first

Ischaemic stroke52Migraine48Pulmonary arterial hypertension41Systemic scleroderma40Coronary artery disease37Arteriosclerosis32Acute myocardial infarction30Hypertension29Pulmonary hypertension24Acute coronary syndrome21Giant cell arteritis18Paroxysmal nocturnal haemoglobinuria17Peripheral arterial occlusive disease17Septic shock17Cardiovascular disorder16Subarachnoid haemorrhage16Acute respiratory distress syndrome15Atrial fibrillation15Anti-neutrophil cytoplasmic antibody positive vasculitis14Cerebrovascular accident14Pulmonary embolism14Embolism13Myocardial infarction13Diabetic foot12+358

Clinical trials in Vascular disorders

846 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

846 clinical trials

Subarachnoid haemorrhage

Not recruiting

Study on the Safety of EDV2209 for Patients with Brain Bleeding (Subarachnoid Hemorrhage)

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:1,4-Diamino-2,3-Dicyano-1,4-Bis(O-Aminophenylmercapto)Butadiene Hemiethanolate
  • Sponsor:Edvince AB

Acromegaly

Not recruiting

Study on the Long-Term Safety and Efficacy of Paltusotine for Patients with Acromegaly

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Paltusotine
  • Sponsor:Crinetics Pharmaceuticals Inc.

Giant cell arteritis

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib and Prednisolone in Patients with Giant Cell Arteritis

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Acute respiratory distress syndrome

Not recruiting

Study on the Effectiveness and Safety of Reparixin for Adults with Acute Respiratory Distress Syndrome

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Reparixin
  • Sponsor:Dompe' Farmaceutici S.p.A.

Aortic stenosis

Not recruiting

Study of spironolactone and Dihydralazine for reducing heart muscle scarring in patients with severe aortic valve narrowing after valve replacement procedure

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Spironolactone
  • Sponsor:Universitaetsmedizin Goettingen

Embolism venous

Not recruiting

Study Comparing Abelacimab and Apixaban for Preventing Blood Clots in Cancer Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Ischaemic stroke

Not recruiting

Study on the Effectiveness of Dornase Alfa for Improving Blood Flow in Patients with Ischemic Stroke Eligible for Thrombectomy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Dornase Alfa
  • Sponsor:Fondation A De Rothschild

Embolism venous+1

Not recruiting

Study on Abelacimab and Dalteparin for Preventing Blood Clots in Patients with Gastrointestinal or Genitourinary Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.

Systemic scleroderma

Not recruiting

Study on Itacitinib for Adults with Diffuse Systemic Sclerosis

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Itacitinib
  • Sponsor:Assistance Publique Hopitaux De Paris

Pulmonary arterial hypertension

Not recruiting

Study Comparing the Effectiveness and Safety of Macitentan 75 mg and 10 mg for Patients with Pulmonary Arterial Hypertension

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Macitentan
  • Sponsor:Actelion Pharmaceuticals Ltd.

Carotid artery occlusion+1

Not recruiting

Study on the Effects of Omalizumab on Carotid Artery Stenosis in Patients Undergoing Carotid Endarterectomy

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Omalizumab
  • Sponsor:Universitair Medisch Centrum Utrecht

Ischaemic stroke+1

Not recruiting

Study of cangrelor with mechanical thrombectomy in patients with acute ischemic stroke selected by perfusion imaging

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cangrelor Tetrasodium
  • Sponsor:Fondation A De Rothschild

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Acetylsalicylic Acid59 clinical trialsSodium Chloride55 clinical trialsClopidogrel33 clinical trialsApixaban28 clinical trialsTicagrelor28 clinical trialsRivaroxaban21 clinical trialsAtorvastatin17 clinical trialsPrasugrel17 clinical trialsRituximab16 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.